# Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

> **NCT00866723** · PHASE2 · TERMINATED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 5 (actual)

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Serous Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00866723
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2011-12
- **Final completion:** 2012-06
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Recruitment has been terminated prematurely because of poor enrollment.
- **Last updated:** 2018-05-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866723, "Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00866723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*